Frank D'alessandro, MD
Internal Medicine · Lincoln, RINPI 1225018955
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,630 of the $92,796 with a category attached, or 78.3%. Novo Nordisk accounts for 89.2% of it on its own, with 54 other manufacturers making up the rest. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $148.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$83K
- AbbVie$1K
- Pfizer$1K
- Sanofi-aventis U.S. LLC$810
- AstraZeneca$798
- Johnson & Johnson$580
- plus $5K from 49 others
Across 99 payments — averaging $4529.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$306K
- Kowa Research Institute, Inc.$101K
- Ironwood Pharmaceuticals, Inc$41K
What the payments were for
- Consulting fees$2,0402%
- Speaking & faculty fees$72,63078%
- Travel & lodging$5,6216%
- Food & beverage$12,49213%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$34,363
- Ozempic$33,966
- Tresiba$5,306
- SOLIQUA 100/33$456
- Truvada$123
- VOQUEZNA$122
- INVOKANA$114
- SHINGRIX$113
- UBRELVY$109
- FreeStyle Libre$106
How this compares
$92,796 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $28,952 |
| FarxigaDapagliflozin Propanediol | 26 | $25,315 |
| OzempicSemaglutide | 23 | $21,273 |
| RybelsusSemaglutide | 15 | $17,163 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,043 |
| JardianceEmpagliflozin | 14 | $10,328 |
| MyrbetriqMirabegron | 15 | $7,797 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,862 |
| Atorvastatin Calcium | 245 | $2,214 |
| Gabapentin | 62 | $1,448 |
| Rosuvastatin Calcium | 45 | $1,178 |
| Lisinopril | 113 | $1,148 |
| Amlodipine Besylate | 122 | $1,136 |
| Losartan Potassium | 124 | $1,072 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 29 | $894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $82,738 | $38,43538 claims |
| PfizerEliquis | $1,119 | $28,95229 claims |
| AstraZenecaFarxiga | $798 | $25,31526 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $444 | $17,90534 claims |
| Boehringer IngelheimJardiance | $135 | $10,32814 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $7,79715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Lincoln
- Christopher SuperczynskiLincoln$9K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Todd ViccioneEast Greenwich$22K
- Brian McCauleyProvidence$20K
- Daniel HochbergerRumford$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.